These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 16759158

  • 21. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
    Fargnoli MC, Gandini S, Peris K, Maisonneuve P, Raimondi S.
    Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [From gene to disease; from p16 to melanoma].
    Gruis NA, Bergman W.
    Ned Tijdschr Geneeskd; 2000 Oct 28; 144(44):2100-2. PubMed ID: 11103670
    [Abstract] [Full Text] [Related]

  • 24. MC1R germline variants confer risk for BRAF-mutant melanoma.
    Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kanetsky PA, Pinkel D, Bastian BC.
    Science; 2006 Jul 28; 313(5786):521-2. PubMed ID: 16809487
    [Abstract] [Full Text] [Related]

  • 25. Identification of five chromosomal regions involved in predisposition to melanoma by genome-wide scan in the MeLiM swine model.
    Geffrotin C, Crechet F, Le Roy P, Le Chalony C, Leplat JJ, Iannuccelli N, Barbosa A, Renard C, Gruand J, Milan D, Horak V, Tricaud Y, Bouet S, Franck M, Frelat G, Vincent-Naulleau S.
    Int J Cancer; 2004 May 20; 110(1):39-50. PubMed ID: 15054867
    [Abstract] [Full Text] [Related]

  • 26. [Molecular biology of familial cases of human melanoma].
    Kit OI, Vodolazhsky DL, Timoshkina NN, Przhedetsky YV, Khokhlova OV.
    Vopr Onkol; 2015 May 20; 61(6):889-97. PubMed ID: 26995975
    [Abstract] [Full Text] [Related]

  • 27. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients.
    Council ML, Gardner JM, Helms C, Liu Y, Cornelius LA, Bowcock AM.
    Exp Dermatol; 2009 May 20; 18(5):485-7. PubMed ID: 19320745
    [Abstract] [Full Text] [Related]

  • 28. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
    Veinalde R, Ozola A, Azarjana K, Molven A, Akslen LA, Doniņa S, Proboka G, Cēma I, Baginskis A, Pjanova D.
    Melanoma Res; 2013 Jun 20; 23(3):221-6. PubMed ID: 23546221
    [Abstract] [Full Text] [Related]

  • 29. No Evidence for BRAF as a melanoma/nevus susceptibility gene.
    Jackson S, Harland M, Turner F, Taylor C, Chambers PA, Randerson-Moor J, Swerdlow AJ, dos Santos Silva I, Beswick S, Bishop DT, Newton Bishop JA.
    Cancer Epidemiol Biomarkers Prev; 2005 Apr 20; 14(4):913-8. PubMed ID: 15824163
    [Abstract] [Full Text] [Related]

  • 30. Melanoma genetics: an update on risk-associated genes.
    Udayakumar D, Tsao H.
    Hematol Oncol Clin North Am; 2009 Jun 20; 23(3):415-29, vii. PubMed ID: 19464594
    [Abstract] [Full Text] [Related]

  • 31. Vitamin D receptor variants and the malignant melanoma risk: a population-based study.
    Gapska P, Scott RJ, Serrano-Fernandez P, Mirecka A, Rassoud I, Górski B, Cybulski C, Huzarski T, Byrski T, Nagay L, Maleszka R, Sulikowski M, Lubinski J, Debniak T.
    Cancer Epidemiol; 2009 Aug 20; 33(2):103-7. PubMed ID: 19679055
    [Abstract] [Full Text] [Related]

  • 32. Management of familial melanoma.
    Bishop JN, Harland M, Randerson-Moor J, Bishop DT.
    Lancet Oncol; 2007 Jan 20; 8(1):46-54. PubMed ID: 17196510
    [Abstract] [Full Text] [Related]

  • 33. The genetics of susceptibility to cutaneous melanoma.
    Newton Bishop JA, Bishop DT.
    Drugs Today (Barc); 2005 Mar 20; 41(3):193-203. PubMed ID: 15883616
    [Abstract] [Full Text] [Related]

  • 34. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B.
    Genes Chromosomes Cancer; 2003 Nov 20; 38(3):265-8. PubMed ID: 14506702
    [Abstract] [Full Text] [Related]

  • 35. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
    Mangas C, Potrony M, Mainetti C, Bianchi E, Carrozza Merlani P, Mancarella Eberhardt A, Maspoli-Postizzi E, Marazza G, Marcollo-Pini A, Pelloni F, Sessa C, Simona B, Puig-Butillé JA, Badenas C, Puig S.
    Br J Dermatol; 2016 Nov 20; 175(5):1030-1037. PubMed ID: 27473757
    [Abstract] [Full Text] [Related]

  • 36. MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients.
    Ghiorzo P, Bonelli L, Pastorino L, Bruno W, Barile M, Andreotti V, Nasti S, Battistuzzi L, Grosso M, Bianchi-Scarrà G, Queirolo P.
    Exp Dermatol; 2012 Sep 20; 21(9):718-20. PubMed ID: 22804906
    [Abstract] [Full Text] [Related]

  • 37. A review of inherited predisposition to melanoma.
    Cannon-Albright LA, Kamb A, Skolnick M.
    Semin Oncol; 1996 Dec 20; 23(6):667-72. PubMed ID: 8970585
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
    Pjanova D, Engele L, Randerson-Moor JA, Harland M, Bishop DT, Newton Bishop JA, Taylor C, Debniak T, Lubinski J, Kleina R, Heisele O.
    Melanoma Res; 2007 Jun 20; 17(3):185-91. PubMed ID: 17505264
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.